DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
109 hedge funds and large institutions have $1.48B invested in DICE Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 12 closing their positions.
250% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 12
120% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 20
98% more capital invested
Capital invested by funds: $748M → $1.48B (+$733M)
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
38% more funds holding
Funds holding: 79 → 109 (+30)
88% less call options, than puts
Call options by funds: $412K | Put options by funds: $3.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$57.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$53.5M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$47.3M |
| 4 |
BlackRock
New York
|
+$37.4M |
| 5 |
Alkeon Capital Management
New York
|
+$33.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$17.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$14.9M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.9M |
| 4 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
-$13M |
| 5 |
PA
Perceptive Advisors
New York
|
-$12.9M |
DICE Hedge Fund Activity: Q4 2022 in Review
109 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q4 2022, worth a combined $1.48B — up 98% from $748M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new DICE positions and 12 closed out — a net gain of 30 holders — while 44 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $57.9M. The largest seller was Janus Henderson Group, cutting an estimated $17.7M.
- 109 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q4 2022, up from 79 in Q3 2022.
- Funds reported $1.48B of DICE Therapeutics, Inc. Common Stock stock for Q4 2022, up 98% quarter-over-quarter.
- 42 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q4 2022 and 12 closed out, a net change of +30 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q4 2022 was Fidelity Investments, an estimated $57.9M added.
- The largest DICE Therapeutics, Inc. Common Stock seller in Q4 2022 was Janus Henderson Group, an estimated $17.7M sold.
Based on aggregated 13F filings for Q4 2022.